Oruka Therapeutics (NASDAQ:ORKA) Shares Down 6.4% - Should You Sell?

Key Points

• Shares fell 6.4% to $59.52 on Friday with about 309,504 shares traded (roughly half the average), leaving a market cap near $2.96 billion and a negative PE of -32.18 while the 50‑ and 200‑day SMAs ($39.02 and $31.78) remain well below the current price.
• Analysts maintain a consensus Moderate Buy with an average target of $64.90 — several firms (Piper Sandler, Stifel, UBS) have lifted targets into the low $70s, though Weiss Ratings still rates the stock a sell.
• Insiders have been net sellers (23,765 shares sold in the last 90 days, including transactions by the CEO) despite insiders owning 24.69% of shares; Oruka is a clinical‑stage biopharma with lead candidate ONCT‑01 in Phase 1 and recently reported Q EPS of -$0.45, beating estimates.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares were down 6.4% on Friday . The stock traded as low as $59.55 and last traded at $59.52. Approximately 309,504 shares changed hands during trading, a decline of 49% from the average daily volume of 610,010 shares. The stock had previously closed at $63.60.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ORKA shares. Piper Sandler started coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an "overweight" rating and a $75.00 target price on the stock. Stifel Nicolaus upped their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, March 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 16th. Finally, UBS Group upped their target price on shares of Oruka Therapeutics from $50.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $64.90.

Oruka Therapeutics Stock Performance

The stock's 50-day simple moving average is $39.02 and its 200 day simple moving average is $31.78. The company has a market capitalization of $2.96 billion, a PE ratio of -32.18 and a beta of -0.54.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.16. On average, analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider directly owned 33,377 shares of the company's stock, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares in the company, valued at $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 23,765 shares of company stock worth $849,575 over the last ninety days. Insiders own 24.69% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ORKA. Goldman Sachs Group Inc. acquired a new stake in Oruka Therapeutics during the 1st quarter worth $2,505,000. JPMorgan Chase & Co. boosted its stake in Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company's stock worth $173,000 after purchasing an additional 13,115 shares during the period. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $28,000. Rhumbline Advisers acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $320,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter worth $96,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.